|
TME Pharma's Ordinary Shares • Date of the IPO: September 28, 2016 *Taking into account the shares issuance following the exercise of Warrants Z as published on March 28, 2025.
TME Pharma's Warrants Z • ISIN NL0015001SR3
Rapid access to French brokers
|
Diede van den Ouden has disclosed plans for initial share purchases to become a more significant shareholder in TME Pharma prior to his nomination for appointment as CEO. See his transactions "I want to commit myself to the success of the company and align my interests with those of other shareholders" M. Diede van den Ouden a annoncé son intention de procéder à des achats d'actions afin d'augmenter sa participation au capital de TME Pharma en amont de sa nomination au poste de PDG. Voir ses transactions « Ma démarche s’inscrit dans une volonté forte de contribuer à la réussite de TME Pharma, tout en renforçant l’alignement de mes intérêts avec ceux des autres actionnaires » Analyst Coverage
TME Pharma N.V. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding TME Pharma’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of TME Pharma or its management. TME Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|
 |
|||||||||
|
|
|||||||||||
